---
document_datetime: 2025-11-23 08:06:06
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-sandoz.html
document_name: pemetrexed-sandoz.html
version: success
processing_time: 0.5312009
conversion_datetime: 2025-12-28 18:14:40.275875
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pemetrexed Sandoz

[RSS](/en/individual-human-medicine.xml/66045)

##### Withdrawn

This medicine's authorisation has been withdrawn

pemetrexed

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pemetrexed Sandoz](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 9 October, the European Commission withdrew the marketing authorisation for Pemetrexed Sandoz (pemetrexed) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sandoz GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Pemetrexed Sandoz was granted marketing authorisation in the EU on 18 September 2015 for the treatment of malignant pleural mesothelioma and non-small cell lung cancer. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2020. The product had not been marketed in the EU since 2024.

Pemetrexed Sandoz is a generic medicine of Alimta. There are other generic medicinal products of Alimta authorised and marketed in the EU. The European Public Assessment Report (EPAR) for Pemetrexed Sandoz is updated to indicate that the marketing authorisation is no longer valid.

Pemetrexed Sandoz : EPAR - Summary for the public

Reference Number: EMA/509171/2015

English (EN) (181.53 KB - PDF)

**First published:** 02/10/2015

**Last updated:** 06/11/2024

[View](/en/documents/overview/pemetrexed-sandoz-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-186)

български (BG) (249.99 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/bg/documents/overview/pemetrexed-sandoz-epar-summary-public_bg.pdf)

español (ES) (182.65 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/es/documents/overview/pemetrexed-sandoz-epar-summary-public_es.pdf)

čeština (CS) (226.94 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/cs/documents/overview/pemetrexed-sandoz-epar-summary-public_cs.pdf)

dansk (DA) (181.76 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/da/documents/overview/pemetrexed-sandoz-epar-summary-public_da.pdf)

Deutsch (DE) (191.49 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/de/documents/overview/pemetrexed-sandoz-epar-summary-public_de.pdf)

eesti keel (ET) (177.65 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/et/documents/overview/pemetrexed-sandoz-epar-summary-public_et.pdf)

ελληνικά (EL) (260.08 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/el/documents/overview/pemetrexed-sandoz-epar-summary-public_el.pdf)

français (FR) (189.38 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/fr/documents/overview/pemetrexed-sandoz-epar-summary-public_fr.pdf)

hrvatski (HR) (216.18 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/hr/documents/overview/pemetrexed-sandoz-epar-summary-public_hr.pdf)

italiano (IT) (184.81 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/it/documents/overview/pemetrexed-sandoz-epar-summary-public_it.pdf)

latviešu valoda (LV) (217.33 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/lv/documents/overview/pemetrexed-sandoz-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (217.69 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/lt/documents/overview/pemetrexed-sandoz-epar-summary-public_lt.pdf)

magyar (HU) (211.11 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/hu/documents/overview/pemetrexed-sandoz-epar-summary-public_hu.pdf)

Malti (MT) (228.56 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/mt/documents/overview/pemetrexed-sandoz-epar-summary-public_mt.pdf)

Nederlands (NL) (188.67 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/nl/documents/overview/pemetrexed-sandoz-epar-summary-public_nl.pdf)

polski (PL) (224.79 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/pl/documents/overview/pemetrexed-sandoz-epar-summary-public_pl.pdf)

português (PT) (185.2 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/pt/documents/overview/pemetrexed-sandoz-epar-summary-public_pt.pdf)

română (RO) (225.9 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/ro/documents/overview/pemetrexed-sandoz-epar-summary-public_ro.pdf)

slovenčina (SK) (215.62 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/sk/documents/overview/pemetrexed-sandoz-epar-summary-public_sk.pdf)

slovenščina (SL) (210.32 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/sl/documents/overview/pemetrexed-sandoz-epar-summary-public_sl.pdf)

Suomi (FI) (179.05 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/fi/documents/overview/pemetrexed-sandoz-epar-summary-public_fi.pdf)

svenska (SV) (181.22 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/sv/documents/overview/pemetrexed-sandoz-epar-summary-public_sv.pdf)

Pemetrexed Sandoz : EPAR - Risk-management-plan summary

Reference Number: EMA/520309/2015

English (EN) (213.08 KB - PDF)

**First published:** 02/10/2015

**Last updated:** 06/11/2024

[View](/en/documents/rmp-summary/pemetrexed-sandoz-epar-risk-management-plan-summary_en.pdf)

## Product information

Pemetrexed Sandoz : EPAR - Product Information

English (EN) (1.75 MB - PDF)

**First published:** 02/10/2015

**Last updated:** 06/11/2024

[View](/en/documents/product-information/pemetrexed-sandoz-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-244)

български (BG) (3.17 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/bg/documents/product-information/pemetrexed-sandoz-epar-product-information_bg.pdf)

español (ES) (2.05 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/es/documents/product-information/pemetrexed-sandoz-epar-product-information_es.pdf)

čeština (CS) (2.58 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/cs/documents/product-information/pemetrexed-sandoz-epar-product-information_cs.pdf)

dansk (DA) (2.14 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/da/documents/product-information/pemetrexed-sandoz-epar-product-information_da.pdf)

Deutsch (DE) (2.05 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/de/documents/product-information/pemetrexed-sandoz-epar-product-information_de.pdf)

eesti keel (ET) (2.31 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/et/documents/product-information/pemetrexed-sandoz-epar-product-information_et.pdf)

ελληνικά (EL) (2.4 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/el/documents/product-information/pemetrexed-sandoz-epar-product-information_el.pdf)

français (FR) (3.07 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/fr/documents/product-information/pemetrexed-sandoz-epar-product-information_fr.pdf)

hrvatski (HR) (2.03 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/hr/documents/product-information/pemetrexed-sandoz-epar-product-information_hr.pdf)

íslenska (IS) (1.66 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/is/documents/product-information/pemetrexed-sandoz-epar-product-information_is.pdf)

italiano (IT) (2.18 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/it/documents/product-information/pemetrexed-sandoz-epar-product-information_it.pdf)

latviešu valoda (LV) (2.28 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/lv/documents/product-information/pemetrexed-sandoz-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.58 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/lt/documents/product-information/pemetrexed-sandoz-epar-product-information_lt.pdf)

magyar (HU) (2.04 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/hu/documents/product-information/pemetrexed-sandoz-epar-product-information_hu.pdf)

Malti (MT) (2.75 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/mt/documents/product-information/pemetrexed-sandoz-epar-product-information_mt.pdf)

Nederlands (NL) (2.28 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/nl/documents/product-information/pemetrexed-sandoz-epar-product-information_nl.pdf)

norsk (NO) (2.12 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/no/documents/product-information/pemetrexed-sandoz-epar-product-information_no.pdf)

polski (PL) (2.37 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/pl/documents/product-information/pemetrexed-sandoz-epar-product-information_pl.pdf)

português (PT) (1.84 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/pt/documents/product-information/pemetrexed-sandoz-epar-product-information_pt.pdf)

română (RO) (2.21 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/ro/documents/product-information/pemetrexed-sandoz-epar-product-information_ro.pdf)

slovenčina (SK) (2.23 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/sk/documents/product-information/pemetrexed-sandoz-epar-product-information_sk.pdf)

slovenščina (SL) (2.58 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/sl/documents/product-information/pemetrexed-sandoz-epar-product-information_sl.pdf)

Suomi (FI) (2.12 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/fi/documents/product-information/pemetrexed-sandoz-epar-product-information_fi.pdf)

svenska (SV) (2.19 MB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/sv/documents/product-information/pemetrexed-sandoz-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000224542 04/09/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pemetrexed Sandoz : EPAR - All Authorised presentations

English (EN) (59.34 KB - PDF)

**First published:** 02/10/2015

**Last updated:** 06/11/2024

[View](/en/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-605)

български (BG) (68.09 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/bg/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_bg.pdf)

español (ES) (60.27 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/es/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_es.pdf)

čeština (CS) (61.13 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/cs/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (89.94 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/da/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (63.34 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/de/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (58.81 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/et/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (67.96 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/el/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_el.pdf)

français (FR) (58.96 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/fr/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (59.48 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/hr/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (89.46 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/is/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_is.pdf)

italiano (IT) (60.38 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/it/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (61.49 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/lv/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (59.69 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/lt/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (64 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/hu/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (63.74 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/mt/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (60.31 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/nl/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (89.8 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/no/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_no.pdf)

polski (PL) (52.87 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/pl/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_pl.pdf)

português (PT) (62.1 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/pt/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_pt.pdf)

română (RO) (60.52 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/ro/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (59.7 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/sk/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (60.64 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/sl/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (86.46 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/fi/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (87.92 KB - PDF)

**First published:**

02/10/2015

**Last updated:**

06/11/2024

[View](/sv/documents/all-authorised-presentations/pemetrexed-sandoz-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pemetrexed Sandoz Active substance pemetrexed disodium hemipentahydrate International non-proprietary name (INN) or common name pemetrexed Therapeutic area (MeSH)

- Carcinoma, Non-Small-Cell Lung
- Mesothelioma

Anatomical therapeutic chemical (ATC) code L01BA04

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

**Malignant pleural mesothelioma**

Pemetrexed Sandoz in combination with cisplatin is indicated for the treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma.

**Non-small cell lung cancer**

Pemetrexed Sandoz in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Pemetrexed Sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Pemetrexed Sandoz is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

## Authorisation details

EMA product number EMEA/H/C/004011

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Sandoz GmbH

Biochemiestr. 10

Opinion adopted 23/07/2015 Marketing authorisation issued 18/09/2015 Withdrawal of marketing authorisation 09/10/2024 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pemetrexed Sandoz : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (186.79 KB - PDF)

**First published:** 29/01/2016

**Last updated:** 06/11/2024

[View](/en/documents/procedural-steps-after/pemetrexed-sandoz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Pemetrexed Sandoz : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/467935/2015

English (EN) (1.06 MB - PDF)

**First published:** 02/10/2015

**Last updated:** 06/11/2024

[View](/en/documents/assessment-report/pemetrexed-sandoz-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pemetrexed Sandoz

Adopted

Reference Number: EMA/CHMP/470192/2015

English (EN) (129.76 KB - PDF)

**First published:** 24/07/2015

**Last updated:** 06/11/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pemetrexed-sandoz_en.pdf)

#### News on Pemetrexed Sandoz

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2015) 24/07/2015

**This page was last updated on** 06/11/2024

## Share this page

[Back to top](#main-content)